51st week of 2021 patent applcation highlights part 26 |
Patent application number | Title | Published |
20210395313 | PEPTIDE PAC1 ANTAGONISTS - Novel peptides that bind to human PAC1 are provided. These peptides that are antagonists of PAC1 are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine, such as acute migraine. | 2021-12-23 |
20210395314 | MODIFIED BACTERIAL MICROCOMPARTMENT SHELL PROTEIN - The present invention provides for a fusion protein comprising (1) a bacterial microcompartment (BMC) shell protein comprising one or more subunit, and (2) a first component of a specific-binding pair, operably linked to the BMC shell protein such that the first component faces (i) a lumen (inside) side, or (ii) outside of a BMC shell formed incorporating the fusion protein and the fusion protein does not disrupt or prevent the folding of the BMC shell protein or the ability of the BMC shell protein to integrate with other BMC shell proteins into a BMC shell; wherein the first component is capable of forming a stable or irreversible interaction with a second component of the specific-binding pair. | 2021-12-23 |
20210395315 | RECOMBINANT LECTIN AND USES THEREOF - Disclosed herein are a recombinant | 2021-12-23 |
20210395316 | TRANSGENIC PLANT HAVING HERBICIDE RESISTANCE - The invention is intended to identify glutathione-S-transferase that exhibits the activities to metabolize and detoxify an isoxazoline derivative, such as pyroxasulfone. The invention provides a method for cultivating a transgenic plant into Which a nucleic acid encoding a protein (a or b) below has been introduced in the presence of isoxazoline derivatives:
| 2021-12-23 |
20210395317 | Protein Fiber Production Method - Disclosed is a method for producing a protein fiber, the method including: bringing a spinning dope containing a protein and an organic solvent into contact with a coagulation liquid to coagulate the protein, wherein a content of the protein in the spinning dope is more than 10% by mass based on a total amount of the spinning dope, and the coagulation liquid contains water or an aqueous solution of pH 0.25 or more and pH 10.00 or less. | 2021-12-23 |
20210395318 | MULTISPECIFIC PROTEINS - The present disclosure relates to multispecific proteins comprising designed ankyrin repeat domains with binding specificity for different targets, such as, e.g. CD40 and FAP. In addition, the present disclosure relates to nucleic acids encoding such multispecific proteins, pharmaceutical compositions comprising such multispecific proteins or nucleic acids, and the use of such binding proteins, nucleic acids or pharmaceutical compositions in methods for treating or diagnosing diseases, such as cancer, in a mammal, including a human. | 2021-12-23 |
20210395319 | METHODS AND COMPOSITIONS COMPRISING TAU OLIGOMERS - Tau protein has a causative role in Alzheimer's disease and multiple other neurodegenerative disorders exhibiting tau histopathology collectively termed tauopathies. The primary function of tau protein is to facilitate assembly and maintenance of microtubules in neuronal axons. In the disease process tau protein becomes modified, loses its affinity to microtubules and accumulates in the cell body where it forms aggregates. The large neurofibrillary tangles formed from tau protein assembled into filaments were thought to be the pathological structure of tau. However, more recent work indicates that smaller, soluble oligomeric forms of tau are best associated with neuron loss and memory impairment. Here, novel compositions of tau oligomers and novel mechanisms for tau oligomer nucleation, extension and termination are taught. Methods for producing and purifying these structures for the development of small molecule and immunotherapeutics as well as antibodies for biomarkers of neurodegenerative diseases are taught. | 2021-12-23 |
20210395320 | PROTEIN HETERODIMER AND USE THEREOF - A protein heterodimer may include a first polypeptide chain and a second polypeptide chain different from the first polypeptide chain, wherein the first polypeptide chain includes IL12a and a first factor fused to IL12a, the second polypeptide chain includes IL12b and a second factor fused to IL12b, and the first factor and the second factor are each independently selected from a group consisting of: IL2, GMCSF, IL7, IL15, IL21, and FLT3L. Such protein heterodimers can be used for treating tumors. | 2021-12-23 |
20210395321 | Colon and Pancreas Cancer Peptidomimetics - The invention relates to a peptidomimetic of an NPC-1 epitope on the MUC5AC protein which is differentially expressed in pancreatic and colorectal cancer, and diagnostic and therapeutic usages. Further, antibodies that selectively bind the NPC-1 epitope peptidomimetics and may be used in diagnostic and therapeutic methods. | 2021-12-23 |
20210395322 | ACTIVIN/BMP7 CHIMERAS: SUPER-ACTIVE SAB704 AND SAB715, AND THEIR RESPECTIVE NOGGINSENSITIZED VARIANTS, NAB704 AND NAB715; AND NAB204 - The present disclosure relates to chimeric polypeptide having TGF-beta activity, nucleic acids encoding the polypeptides, and host cells for producing the polypeptides with improved or novel biological and therapeutic properties. | 2021-12-23 |
20210395323 | TUMOR NECROSIS FACTOR RECEPTOR (TNFR) BINDING PROTEIN COMPLEX WITH IMPROVED BINDING AND BIOACTIVITY - The present invention relates to a tumor necrosis factor receptor (TNFR) binding protein complex comprising 12 or more N protein ligands (PLs) that specifically bind to the extracellular part of the same TNFR. Preferably, the TNFR binding protein complex binds to the extracellular part of TNFR2. Preferably, the TNFR binding protein complex of the present invention further comprises a two or more polymerization domains (PD). | 2021-12-23 |
20210395324 | MULTI-LEVEL SPECIFIC TARGETING OF CANCER CELLS - A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13Rα2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; and a subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule (and preferably with said cytosol localization element between said binding ligand and said subcellular compartment localization signal element). Methods of using such compounds and formulations containing the same are also described. | 2021-12-23 |
20210395325 | IL-2 FUSION POLYPEPTIDE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME - Provided herein are compositions comprising polypeptides comprising a circularly permuted interleukin-2 (IL-2) fused to the extracellular portion of an IL-2Rα chain, and methods of making and using such compositions. | 2021-12-23 |
20210395326 | THERAPEUTIC COMPOUNDS AND METHODS - This disclosure describes engineered compounds that engage NK cells and methods of using the compounds. Generally, the compound includes an NK engaging domain, a targeting domain that selectively binds to a target cell, and an NK activating domain operably linking the NK engaging domain and the targeting domain. | 2021-12-23 |
20210395327 | Growth Hormone-Releasing Hormone Antagonists and Uses Thereof - Described herein are compositions and methods for treating pulmonary fibrosis and cancer. The compositions include growth hormone releasing hormone peptides. The methods include reducing lung inflammation, lung scarring, reducing expression of T cell receptor complex genes as well as inhibiting tumor growth. | 2021-12-23 |
20210395328 | METHOD FOR MODIFICATION OF POLYPETIDE AND USES - Provided are a method for the modification of a polypeptide and uses. The method comprises the following steps: (1) introducing an X into the N-terminus of a polypeptide, thereby obtaining X-polypeptide; (2) oxidizing the X into an aldehyde group; (3) adding a reducing agent, and covalently coupling the oxidation product obtained in step (2) with PEG, thereby obtaining a PEG-modified polypeptide, wherein X is threonine or serine. In the present application, a single component of PEG-modified polypeptide is obtained by introducing a threonine or serine into the N-terminus of the polypeptide, and deriving the amino alcohol structure at the ortho-position of the N-terminus of the polypeptide as an aldehyde group by using a high-specificity oxidation method and covalently coupling the aldehyde group with PEG. The method has a strong universality and a wide range of application, and the method for separating the modified polypeptide is simple and convenient, thereby improving the stability and the circulating half-life of the polypeptide. | 2021-12-23 |
20210395329 | CD6 TARGETED CHIMERIC ANTIGEN RECEPTORS FOR TREATENT OF CERTAIN AUTOIMMUNE DISORDERS - Provided herein are, inter alia, CD6 targeting CAR-T cell compositions and methods useful for treating autoimmune diseases (e.g., Type I diabetes). | 2021-12-23 |
20210395330 | T-CELL RECEPTOR RECOGNIZING SSX2 ANTIGEN - A T cell receptor (TCR) capable of specifically binding to a short peptide KASEKIFYV derived from an AFP antigen. The antigen short peptide KASEKIFYV can form a complex with HLA A0201 and be presented together with same to the cell surface. A nucleic acid molecule encoding the TCR, a vector comprising the nucleic acid molecule, and a cell that transduces the TCR. | 2021-12-23 |
20210395331 | T CELL RECEPTOR - The present invention provides an engineered T cell receptor (TCR) comprising at least one of the following amino acid residues: L96 of the α chain; R9 of the β chain; Y10 of the β chain; T24 of the α chain; V19 of the α chain; T20 of the α chain; M50 of the α chain; T5 of the α chain; Q8 of the α chain; S86 of the α chain; F39 of the α chain; D55 of the α chain; R43 of the β chain; A66 of the α chain; V19 of the β chain; L21 of the β chain; L103 of the β chain; T3 of the α chain; S7 of the α chain; P9 of the α chain; M11 of the α chain; A16 of the α chain; T18 of the α chain; L21 of the α chain; S22 of the α chain; D26 of the α chain; F40 of the α chain; S47 of the α chain; R48 of the α chain; Q49 of the α chain; 151 of the α chain; L52 of the α chain; V53 of the α chain; T67 of the α chain; E68 of the α chain; N74 of the α chain; F76 of the α chain; N79 of the α chain; Q81 of the α chain; A83 of the α chain; K90 of the α chain; S92 of the α chain; D93 of the α chain; and M101 of the α chain; wherein the at least one amino acid residue is not present in the corresponding germline TCR amino acid sequence. | 2021-12-23 |
20210395332 | TCR LIBRARIES - The present invention relates to a library of particles, the library displaying a plurality of different T cell receptors (TCRs), wherein the plurality of TCRs consists essentially of TCRs comprising an alpha chain variable domain and a beta chain variable domain, wherein the alpha chain variable domain comprises a TRAV12-2 gene product and the beta chain variable domain comprises a TRBV gene product. | 2021-12-23 |
20210395333 | MULTIMERIC PROTEINS FOR DETECTING A CARBOHYDRATE AND/OR TREATING A SIGLEC-MEDIATED DISORDER - The invention relates generally to polypeptides comprising a lectin domain, multimeric proteins comprising the polypeptides, and use of the polypeptides or multimeric proteins in the detection of a carbohydrate (e.g., a sialic acid containing carbohydrate or Siglec ligand) or the treatment of a Siglec-mediated disorder. | 2021-12-23 |
20210395334 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2021-12-23 |
20210395335 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2021-12-23 |
20210395336 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2021-12-23 |
20210395337 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2021-12-23 |
20210395338 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2021-12-23 |
20210395339 | GROWTH FACTOR ANTAGONISTS FOR ORGAN TRANSPLANT ALLOIMMUNITY AND ARTERIOSCLEROSIS - The present invention provides materials and methods for antagonizing the function of vascular endothelial growth factor receptors, platelet derived growth factor receptors and other receptors, to prevent, inhibit, or ameliorate allograft rejection or arteriosclerosis in organisms that receive an organ transplant. | 2021-12-23 |
20210395340 | IL4/IL13 Receptor Molecule for Veterinary Use - Provided are various embodiments relating to IL13R/IL4R heterodimeric proteins derived from companion animal species and that bind to IL13 and/or IL4. Such heterodimeric proteins can be used in methods to treat IL13 and/or IL4-induced conditions in companion animals, such as canines, felines, and equines. | 2021-12-23 |
20210395341 | COMPOSITIONS AND METHODS FOR ANTI-THROMBOTIC AND HEMOSTATIC THERAPIES - In various embodiments, disclosed herein are methods of assessing therapeutic efficacy of an anticoagulant. Preferably, the method comprising providing a blood sample; perfusing the blood sample over a surface coated with collagen or immobilized rTF; measuring platelet aggregation and fibrin deposition on the surface coated with collagen or immobilized rTF; and assessing therapeutic efficacy of the anticoagulant based on the volume of platelet aggregates and/or deposited fibrin. | 2021-12-23 |
20210395342 | PEPTIDE COMPOUNDS FOR SUPPRESSING INFLAMMATION - Provided herein are peptides that exhibit ApoE biological activity, as well as compositions and pharmaceutical formulations that include the peptides. The peptides, compositions, and methods disclosed herein have broad applications as they can be used to treat a broad spectrum of injury, diseases, disorders, and clinical indications. | 2021-12-23 |
20210395343 | IVIG COMPOSITION AND METHOD OF TREATMENT OF ANTIBODY DEFICIENT PATIENTS - The invention is in the field of therapy of antibody deficiencies such as immune diseases and inflammatory disorders. The inventors demonstrate for the first time the convergence of intestinal IgA and serum IgG responses toward the same microbial targets, under homeostatic conditions. Private anti-microbiota IgG specificities are induced in IgA-deficient patients, but are not found in IgG pools from healthy donors, partially explaining why substitutive IgG (IVIG) cannot regulate antibody deficiency-associated gut dysbiosis and intestinal translocation. Finally, in both controls and IgA-deficient patients, systemic anti-microbiota IgG responses correlate with reduced inflammation suggesting that systemic IgG responses contribute to the gut microbiota confinement. Accordingly, the invention relates to IVIGs (Intravenous immunoglobulins) composition containing at least 1% of immunoglobulins (Ig) from SIgAd (Selective IgA deficiency) patient and their use in the treatment of antibody deficiency disorders such as immune diseases, inflammatory disorders and autoimmune disease. | 2021-12-23 |
20210395344 | VARIANT NUCLEIC ACID LIBRARIES FOR CORONAVIRUS - Provided herein are methods and compositions relating to libraries of optimized antibodies having nucleic acids encoding for an antibody comprising modified sequences. Libraries described herein comprise nucleic acids encoding SARS-CoV-2 or ACE2 antibodies. Further described herein are protein libraries generated when the nucleic acid libraries are translated. Further described herein are cell libraries expressing variegated nucleic acid libraries described herein. | 2021-12-23 |
20210395345 | Methods for Treating or Preventing SARS-CoV-2 Infections and COVID-19 with Anti-SARS-CoV-2 Spike Glycoprotein Antibodies - The present invention provides methods for preventing and treating SARS-CoV-2 infections, COVID-19, or symptoms thereof. The methods of the invention feature the administration of one or more antigen-binding molecules (e.g., antibodies) that bind a surface protein of SARS-CoV-2 (e.g., spike protein). | 2021-12-23 |
20210395346 | STEREOTYPIC NEUTRALIZING VH CLONOTYPES AGAINST SARS-COV-2 RBD IN COVID-19 PATIENTS AND THE HEALTHY POPULATION - Described are stereotypic-naïve SARS-CoV-2 neutralizing antibodies that inhibit that SARS-CoV-2 virus replication. The antibodies comprise variable heavy chain (VH) clonotypes, encoded by either immunoglobulin heavy variable (IGHV)3-53 or IGHV3-66 and immunoglobulin heavy joining (IGHJ)6, and were identified in IgM, IgG3, IgG1, IgA1, IgG2, and IgA2 subtypes, with minimal somatic mutations, and could be paired with diverse light chains, resulting in binding to the SARS-CoV-2 receptor-binding domain (RBD). One of these clonotypes potently inhibited viral replication. Interestingly, these VH clonotypes pre-existed in six of 10 healthy individuals, predominantly as IgM isotypes, which could explain the expeditious and stereotypic development of these clonotypes among SARS-CoV-2 patients | 2021-12-23 |
20210395347 | NS1-BINDING PROTEIN - Provided is an isolated binding protein including an antigen binding domain binding to an NS1 protein, and including specific heavy chain CDR and light chain CDR. The binding protein can specifically identify and bind to NS1, and has relatively high sensitivity and specificity, so as to detect dengue vims. Moreover, the binding protein does not need to be produced by injecting hybridoma cells into mouse peritoneal cavity, while simplifying production, thus stabilizing antibody functionality. | 2021-12-23 |
20210395348 | COMPOSITION FOR THE TREATMENT OF ANTIBODY DEFICIENCIES - The invention is in the field of therapy of antibody deficiencies. Inventors demonstrate for the first time in both controls and IgA-deficient patients, systemic anti-microbiota IgG responses correlate with reduced inflammation suggesting that systemic IgG responses contribute to the gut microbiota confinement. Furthermore, SIgAd-associated inflammation is inversely correlated with systemic anti-commensal IgG responses, which may thus serve as a second line of defense. Altogether, these data suggest that systemic IgG and intestinal IgA cooperate in different body compartments to limit systemic pro-inflammatory pathways. As selective IgA deficient patients harbour elevated seric anti-commensal IgG levels, these findings suggest that in selective IgA deficiency, microbiota confinement is obtained at the price of a strong inflammatory response. Accordingly, the invention relates to a composition containing immunoglobulins A (IgA), more particularly secretory IgA, for use by oral administration in the prevention or treatment of antibody deficiencies such as SIgAd (Selective IgA deficiency) or common variable immunodeficiency (CVID) and associated inflammatory diseases. | 2021-12-23 |
20210395349 | ANTI-TAU CONSTRUCTS - The present invention provides anti-tau constructs. Anti-tau constructs of the invention are polynucleotide sequences encoding a polypeptide comprising at least one tau binding moiety and optionally comprising a signal peptide and/or a purification moiety. The present invention also provides isolated polypeptides encoded by anti-tau constructs, vectors comprising anti-tau constructs, and isolated cells comprising said vectors. | 2021-12-23 |
20210395350 | ANTIBODIES BINDING TO CITRULLINATED HISTONE 2A AND/OR 4 - The invention provides antibodies or binding fragments thereof directed against citrulline-containing epitopes. The antibodies or binding fragments thereof of the invention can be used in therapy, for example in the treatment or prevention of Neutrophil Extracellular Trap (NET)-associated pathologies. | 2021-12-23 |
20210395351 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER - Provided herein is a pharmaceutical combination comprising SFRP2 antagonist and an PD-1 antibody antagonist. The invention also provides a method for the treatment of cancer, comprising the administration of a therapeutically effective amounts of a SFRP2 antagonist and a PD-1 antagonist to a patient in need thereof. | 2021-12-23 |
20210395352 | SUBCUTANEOUS DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) - Provided are methods for clinical treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) comprising administering to the patient an anti-C5 antibody, or antigen binding fragment thereof, wherein the anti-C5 antibody, or antigen binding fragment thereof, is administered (or is for administration) subcutaneously according to a particular clinical dosage regimen (i.e., at a particular dose amount and according to a specific dosing schedule). In one embodiment, the patient has previously been treated with eculizumab (Soliris®). | 2021-12-23 |
20210395353 | INHIBITORS OF COMPLEMENT FACTOR H - Disclosed herein are Complement factor H (CFH) inhibitors, such as anti-CFH antibodies and small molecules, and methods of using said inhibitors. | 2021-12-23 |
20210395354 | ANTI-HUMAN NGF ANTIBODIES AND METHODS USING SAME - The invention provides an antibody and/or an antigen binding fragment that binds to NGF, and the amino acid sequences of the heavy chain and light chain variable regions of the antibody. The NGF antibody and/or its antigen binding fragment provided by the invention has high affinity for NGF and can effectively block the binding between NGF receptor and NGF. This antibody and/or its antigen binding fragment can inhibit the binding activity of NGF and its receptor in vitro, and is suitable for the treatment of pain diseases which are related to the haughty expression or increased expression of NGF. | 2021-12-23 |
20210395355 | HUMAN FCRN-BINDING MODIFIED ANTIBODIES AND METHODS OF USE - Herein is reported the use of an antibody comprising an Fc-region with abolished FcRn binding for the transport of a soluble receptor ligand from the eye over the blood-ocular-barrier into the blood circulation. | 2021-12-23 |
20210395356 | CROSS-SPECIES ANTI-LATENT TGF-BETA 1 ANTIBODIES AND METHODS OF USE - The objective of the invention is to provide cross-species anti-latent TGF-beta 1 antibodies which inhibit a protease mediated activation of latent TGF-beta 1 without inhibiting integrin mediated activation of latent TGF-beta 1. To obtain the anti-latent TGF-beta 1 antibodies of the invention, anti-latent-latent TGF-beta 1 antibodies which inhibit a protease mediated activation of latent TGF-beta 1 without inhibiting integrin mediated activation of latent TGF-beta 1 were screened, and then humanized, and further optimized. The invention also provides combination therapies comprising an anti-latent TGF-beta 1 antibody and one or more immune checkpoint inhibitors, preferably a PD-1 axis binding antagonists. | 2021-12-23 |
20210395357 | HUMANIZED MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN-6, ENCODING GENES AND USES THEREOF - The present invention relates to an anti-IL-6 antibody, a pharmaceutical composition or a kit comprising the same, and uses thereof. | 2021-12-23 |
20210395358 | USE OF CLAZAKIZUMAB TO DESENSITIZE AND IMPROVE RENAL TRANSPLANTATION IN HLA-SENSITIZED PATIENTS - Methods for desensitization of patients in need of organ transplant are provided Human leukocyte antigen-sensitized patients awaiting incompatible kidney transplant have been treated with clazakizumab to show reduced or eliminated levels of donor-specific antibodies and an improved transplant rate Clazakizumab and variants are provided for use in various embodiments of the methods. In some embodiments, clazakizumab, or its variants, is administered simultaneously or sequentially with intravenous immunoglobulin. | 2021-12-23 |
20210395359 | Weight Loss Regimen - Obesity and/or diabetes are treated by partially inhibiting circulating leptin in a person in need thereof. | 2021-12-23 |
20210395360 | SP35 Antibodies And Uses Thereof - Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody. | 2021-12-23 |
20210395361 | ANTI-SIGLEC-5 ANTIBODIES AND METHODS OF USE THEREOF - The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a Siglec-5 protein, e.g., human Siglec-5, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof. | 2021-12-23 |
20210395362 | CAR-T CELLS WITH HUMANIZED CD19 SCFV WITH MUTATION IN CDR 1 REGION - Provided is a humanized CD19 single-chain variable fragment (scFv) having a mutation of valine to glycine in CDR1, comprising VH having the amino acid sequence of SEQ ID NO: 6 and VL having the amino acid sequence of SEQ ID NO: 5. Also provided is a CD19 chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv), (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. This humanized CD19-CAR-T cells have specific killing activity with secretion of cytokine IFN-gamma in CAR-T cells in vitro and in vivo. | 2021-12-23 |
20210395363 | METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS - The present invention relates to immunoglobulins that bind FcγRIIb+ cells and coengage the antigen on the cell's surface and an FcγRIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins. | 2021-12-23 |
20210395364 | CAR-T CELLS WITH HUMANIZED CD19 SCFV - The present invention is directed to a humanized CD19 single-chain variable fragment (scFv), comprising the amino acid sequence of SEQ ID NO: 8. The present invention is also directed to a CD19 chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. The humanized anti-CD19 scFv of the present invention exhibits selective and high-affinity binding to CD19. CD19-CAR T cells based on humanized scFv of the present invention are useful to treat patients with B-cell malignancies including leukemia and lymphomas. | 2021-12-23 |
20210395365 | CHECKPOINT BLOCKADE AND MICROSATELLITE INSTABILITY - Blockade of immune checkpoints such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) shows promise in patients with cancer. Inhibitory antibodies directed at these receptors have been shown to break immune tolerance and promote anti-tumor immunity. These agents work particularly well in patients with a certain category of tumor. Such tumors may be particularly susceptible to treatment because of the multitude of neoantigens which they produce. | 2021-12-23 |
20210395366 | TREATMENT WITH ANTI-TIGIT ANTIBODIES AND PD-1 AXIS BINDING ANTAGONISTS - The present invention relates to the treatment of esophageal cancer, e.g., esophageal squamous cell carcinoma (ESCC) (e.g., advanced ESCC (e.g., unresectable, locally advanced, recurrent, and/or metastatic ESCC)). More specifically, the invention pertains to the treatment of patients having esophageal cancer by administering a combination of an anti-T-cell immunoreceptor with Ig and ITIM domains (TIGIT) antagonist antibody and a programmed death-1 (PD-1) axis binding antagonist. | 2021-12-23 |
20210395367 | DOSING - The present invention relates to a method of treating cancer comprising administering to the human an ICOS binding protein or antigen binding portion thereof at a dose of about 0.08 mg to about 240 mg. | 2021-12-23 |
20210395368 | ANTI-PD-1 VACCINE COMPOSITION - The present invention relates to a polypeptide which comprises or consists of—a first sequence consisting of at least 8 contiguous amino acid residues selected from within the sequence extending from amino acid residues 55 to 67 of the PD-L1 protein, and at most 30 contiguous amino acid residues selected from within the complete sequence of the PD-L1 protein; and/or—a second sequence consisting of at least 8 contiguous amino acid residues selected from within the sequence extending from amino acid residues 85 to 101 of the PD-L1 protein, and at most 30 contiguous amino acid residues selected from within the complete sequence of the PD-L1 protein; and/or—a third sequence consisting of at least 8 contiguous amino acid residues selected from within the sequence extending from amino acid residues 111 to 127 of the PD-L1 protein, and at most 30 contiguous amino acid residues selected from within the complete sequence of the PD-L1 protein; and/or—a fourth sequence consisting of at least 8 contiguous amino acid residues selected from within the sequence extending from amino acid residues 138 to 156 of the PD-L1 protein, and at most 30 contiguous amino acid residues selected from within the complete sequence of the PD-L1 protein; and/or—a fifth sequence consisting of at least 8 contiguous amino acid residues selected from within the sequence extending from amino acid residues 208 to 223 of the PD-L1 protein, and at most 30 contiguous amino acid residues selected from within the complete sequence of the PD-L1 protein. | 2021-12-23 |
20210395369 | ANTI-B7-H3 MONOCLONAL ANTIBODY AND USE THEREOF IN CELL THERAPY - The present invention provides an anti-B7-H3 monoclonal antibody and use thereof in cell therapy. Specifically, the present invention provides an scFv, an antibody, and a specific CAR-T cell specifically targeting B7-H3. The present invention further provides an engineered immune cell capable of co-expressing a CAR targeting B7-H3 and a chimeric molecule or a secreted protein of PD-L1, the engineered immune cell having good tumor killing effects. | 2021-12-23 |
20210395370 | METHOD FOR PURIFYING ACTIVE POLYPEPTIDES OR IMMUNOCONJUGATES - The present invention provides methods for isolating an active polypeptide or immunoconjugate by purification of a solution containing both the active polypeptide or immunoconjugate and an acidic variant thereof, such as a deamidated variant, using anion exchange chromatography. The present invention also provides compositions, formulations, and unit dosage forms comprising the purified polypeptide or immunoconjugate. | 2021-12-23 |
20210395371 | PREPARATION AND USE OF ANTI-MET-AND-RON BISPECIFIC ANTIBODY AND ANTIBODY-DRUG CONJUGATE THEREOF - Provided herein are a preparation method and use of an anti-MET-and-RON bispecific antibody and an antibody-drug conjugate thereof. The anti-MET-and-RON bispecific antibody includes an anti-MET antibody fragment and an anti-RON antibody fragment which are linked to each other through a specific chemical “knobs-into-holes” structure. | 2021-12-23 |
20210395372 | ANTI-MET FAB-FC FOR THE TREATMENT OF A TUMOR AND/OR METASTASIS - An anti-Met antibody fragment comprising a single antigen binding arm and an Fc region, wherein the antigen binding arm is defined by the variable regions having amino acid sequences as set forth in SEQ ID No.: 7, 8 and wherein the anti-Met antibody fragment is useful in the treatment of a tumor and/or metastasis. | 2021-12-23 |
20210395373 | Bispecific EGFR/C-Met Antibodies - Bispecific EGFR/c-Met antibodies and methods of making and using the molecules. | 2021-12-23 |
20210395374 | Bispecific CD123 x CD3 Diabodies for the Treatment of Hematologic Malignancies - The present invention is directed to a method of treating a hematologic malignancy such as acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), including hematologic malignancies that are refractive to chemotherapeutic and/or hypomethylating agents. The method concerns administering a CD123×CDS bispecific binding molecule to a patient in an amount effective to stimulate the killing of cells of said hematologic malignancy in said patient. The present invention is additionally directed to the embodiment of such method in which a cellular sample from the patient evidences an expression of one or more target genes that is increased relative to a baseline level of expression of such genes, for example, a baseline level of expression of such genes in a reference population of individuals who are suffering from the hematologic malignancy, or with respect to the level of expression of a reference gene. | 2021-12-23 |
20210395375 | INTERFERON RECEPTOR 1 ANTIBODIES AND THEIR USES - The present invention provides isolated human monoclonal antibodies that bind to IFNAR-1 and that are capable of inhibiting the biological activity of Type I interferons. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting Type I interferon-mediated disorders using the antibodies of the invention, including methods for treating autoimmune disorders, transplant rejection or Graft Versus Host Disease using the antibodies of the invention. | 2021-12-23 |
20210395376 | ANTIBODIES AND POLYPEPTIDES DIRECTED AGAINST CD127 - The invention is in the field of antibodies useful in therapeutic and diagnostics applications targeting CD127, the alpha chain of the IL7 receptor, and provides in particular humanized monoclonal antibodies against CD127, particularly human CD127, therapeutic uses thereof, and diagnostics applications. | 2021-12-23 |
20210395377 | METHODS AND COMPOSITIONS RELATING TO ANTI-CHI3L1 ANTIBODY REAGENTS FOR THE TREATMENT OF FIBROSIS - Described herein are methods and compositions relating to anti-CHI3L1 antibodies, antibody reagents, and antigen-binding fragments thereof which display superior properties, e.g., high sensitivity, high specificity, high binding affinity, neutralization activity ex vivo and in vivo (e.g., blocks CHI3L1-induced MARK and AKT signaling) Methods of treatment, e.g., of treating fibrosis by administering the compounds described herein are also provided. | 2021-12-23 |
20210395378 | ANTIBODIES, USES & METHODS - The present invention related to anti-human OX40L antibodies, new medical uses and methods. | 2021-12-23 |
20210395379 | ANTIBODIES TARGETING CD137 AND METHODS OF USE THEREOF - The present invention relates to an isolated antibody which specifically binds human CD137, and pharmaceutical compositions and methods of use thereof. The present invention further relates to a nucleic acid comprising a nucleotide sequence encoding said antibody, a vector comprising said nucleic acid, a host cell comprising said nucleic acid or said vector, and a method of producing said antibody. | 2021-12-23 |
20210395380 | VARIANT ANTIBODIES THAT BIND OX40 - The present disclosure provides variant anti-OX40 antibodies that mimic the activity of OX4OL by behaving as an agonist against receptor OX40 to enhance T cell clonal expansion and differentiation. The variant anti-OX40 antibodies exhibit improved binding affinity for OX40 and improved agnostic activity, compared to a wild type anti-OX40 antibody (wild type 2B4 clone) from which the variant clones are derived. The variant anti-OX40 antibodies specifically bind OX40 receptors on activated T lymphocytes, stimulate proliferation of effector T cells, stimulate proliferation of effector T cells in the presence of regulatory T cells, and stimulate production of at least one cytokine from effector T cells. | 2021-12-23 |
20210395381 | TFR-SPECIFIC BINDING MOIETIES AND TRANSCYTOSIS METHOD TO SELECT VNARS THAT CROSS CELLULAR BARRIERS - The present invention relates to the fields of molecular medicine and targeted delivery of therapeutic or diagnostic agents to cells outside the vascular system and into the parenchymal tissue of organs within the body. More specifically, the present invention relates to improved TfR-binding moieties capable of crossing the blood brain barrier (BBB) and capable of carrying and releasing cargo specifically targeted to the parenchymal tissue of the brain. The present invention relates to a transcytosis selection method to obtain VNARs against mammalian blood brain barrier (BBB) receptors using phage display libraries as well as against receptors found in other directional cell barrier systems like the gastrointestinal tract and other organs. The VNARs may be used alone or as components in compositions or as conjugates that target the particular receptor transport systems for delivery of therapeutics or diagnostics to the brain (in the case of BBB receptors) or other tissues. | 2021-12-23 |
20210395382 | COMPOSITIONS AND METHODS FOR TREATING CANCER - Provided herein are compositions and methods for cancer immunotherapy. In particular, provided herein are compositions and methods for blocking CD6 binding to ligands on cancer cells. | 2021-12-23 |
20210395383 | ANTI-PSGL-1 ANTIBODIES AND USES THEREOF - Provided herein, in one aspect, are antibodies that immunospecifically bind to PSGL-1, polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to PSGL-1, as well as methods of treating a disorder or disease caused by or associated with increased proliferation and/or numbers of activated T cells using the antibodies described herein. | 2021-12-23 |
20210395384 | HUMAN ANTIBODY DRUG CONJUGATES AGAINST TISSUE FACTOR - Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapeutic and diagnostic methods for using the antibodies and antibody drug conjugates. | 2021-12-23 |
20210395385 | EFFICACY OF ANTI-TROP-2-SN-38 ANTIBODY DRUG CONJUGATES FOR THERAPY OF TUMORS RELAPSED/REFRACTORY TO CHECKPOINT INHIBITORS - The present invention relates to therapeutic ADCs comprising SN-38 attached to an anti-Trop-2 antibody or antigen-binding antibody fragment, more particularly sacituzumab govitecan. The ADC is administered to a subject with a Trop-2 positive cancer that is resistant to or relapsed from prior treatment with a checkpoint inhibitor. The therapy is effective to treat cancers that are resistant to checkpoint inhibitors. | 2021-12-23 |
20210395386 | CHIMERIC POLYPEPTIDES AND METHODS OF ALTERING THE MEMBRANE LOCALIZATION OF THE SAME - Methods and compositions are provided for reversibly localizing proteins to the exterior part of the cell surface. Compositions provided herein can include nucleic acids that encode polypeptides of interest and the ligand binding domain (LBD) of a nuclear hormone receptor. Medical applications are provided, including controlling the toxicity of CAR T cells. | 2021-12-23 |
20210395387 | ANTIBODY CONJUGATE, AND RELATED PHARMACEUTICAL COMPOSITION AND APPLICATION - The present invention relates to a multi-specific antibody conjugate (such as, a bispecific antibody conjugate), and a related composition, therapeutic method and use thereof. The antibody conjugate comprises a multispecific antibody, such as a bispecific antibody, conjugated to a nanomaterial. The antibody conjugate can be used to modulate an immune response, treat or prevent a disease or condition (e.g., a cancer, autoimmune disease, pathogen infection or inflammatory disease), etc. | 2021-12-23 |
20210395388 | Antigen-Binding Constructs Targeting HER2 - Described herein are high affinity antigen binding constructs, e.g., antibodies, directed to the ECD2 domain of HER2. The antigen-binding constructs comprise at least one antigen-binding polypeptide construct that binds to ECD2 of HER2 (HER2 ECD2) with increased affinity compared to a wild-type 2C4 antibody. Such antigen-binding polypeptide constructs comprise one or more amino acid modifications in the framework region and/or CDRs compared to the amino acid sequence of a wild-type 2C4 antibody that increase affinity of the antigen-binding polypeptide construct for ECD2 by 2-fold or greater. The antigen-binding constructs can inhibit the growth of HER2-expressing breast cancer cells and gastric cancer cells. Antigen-binding constructs in biparatopic format are internalized in HER2-expressing cells. | 2021-12-23 |
20210395389 | HER-2 Binding Antibodies - The present invention relates to monoclonal antibodies that specifically bind to HER2, or a fragment or derivative thereof or a polypeptide that contains at least a portion of said antibody that is sufficient to confer specific HER2 binding to the polypeptide. Said antibodies bind to the human Fc receptor and induce FcR mediated signaling pathways. The antibodies according to the invention bind to a different epitope than trastuzumab. | 2021-12-23 |
20210395390 | REVERSAL AGENTS FOR NEUTRALIZING THE THERAPEUTIC ACTIVITY OF ANTI-FXIA ANTIBODIES - The present invention relates to reversal agents, which specifically bind to the anti-FXIa antibody 076D-M007-H04-CDRL3-N110D as described in WO2013/167669, and neutralize the therapeutic activity of this anti-FXIa antibody, as well as to compositions comprising these reversal agents. Methods of obtaining the antibodies or antigen-binding fragments thereof (such as Fab fragments) and nucleic acids encoding the same, are also provided. Furthermore, the invention relates to methods of use of these reversal agents, such as methods for neutralizing the therapeutic activity of the anti-FXIa antibody 076D-M007-H04-CDRL3-N110D, and to related methods as essential part of a general bleeding management. | 2021-12-23 |
20210395391 | Dosage Regimen for TFPI Antagonists - Dosing regimens for the treatment of coagulation disorders using anti-TFPI antibodies are provided. The methods comprises administering to a subject in need there of an initial dose of about 50 mg to 500 mg of an anti-TFPI antibody or antigen-binding fragment thereof. | 2021-12-23 |
20210395392 | ANTI-MERTK ANTIBODIES FOR TREATING CANCER - This disclosure provides isolated antibodies that bind specifically to MerTK expressed on the surface of a cell and inhibit efferocytosis by the MerTK-expressing cell. The disclosure provides methods for treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an anti-MerTK antibody as monotherapy or in combination with a checkpoint inhibitor, such as an anti-PD-1 or anti-PD-L1 antibody. | 2021-12-23 |
20210395393 | TISSUE PLASMINOGEN ACTIVATOR ANTIBODIES AND METHOD OF USE THEREOF - The present invention provides tissue plasminogen activator antibody molecules and their uses. More particularly, the presently-disclosed invention provides humanised antibody molecules which specifically bind tissue plasminogen activator (TPA) and their use in treating TPA induced haemorrhage, in particular treating systemic haemorrhage such as brain haemorrhage after treatment of ischemic stroke or myocardial infarction, or systemic bleeding after TPA treatment of pulmonary embolism, ischemic stroke or myocardial infarction. | 2021-12-23 |
20210395394 | Antibody against pan-species-specific plasmodium lactate dehydrogenase - Provided are an isolated binding protein including a pan-species-specific | 2021-12-23 |
20210395395 | ENGINEERED IGA ANTIBODIES AND METHODS OF USE - Provided herein are engineered antibodies that comprise a modified IgA heavy chain constant region, pharmaceutical compositions, and methods of use. The engineered antibodies described herein comprise one or more amino acid substitution or deletion in a constant region of an IgA domain. Further provided herein are methods of treating disorders, including cancer, by administering an engineered IgA antibody described herein. | 2021-12-23 |
20210395396 | HER2-BINDING TETRAMERIC POLYPEPTIDES - The invention relates to a tetrameric polypeptide comprising a first polypeptide chain comprising a first VL antigen binding domain and a first CL constant domain, a second polypeptide chain comprising a first VH antigen binding domain, a first CH1 constant domain, a first CH2 constant domain and a first CH3 constant domain, a first ligand binding to a HER2 D4 epitope linked to the N-terminus of said first VL antigen binding domain or said first VH antigen binding domain by a first interdomain amino acid linker, a third polypeptide chain comprising a second VL antigen binding domain and a second CL constant domain, a fourth polypeptide chain comprising a second VH antigen binding domain, a second CH1 constant domain, a second CH2 constant domain and a second CH3 constant domain and a third ligand binding to a HER2 D4 epitope linked to the N-terminus of said second VL antigen binding domain or said second VH antigen binding domain by a second interdomain amino acid linker, wherein the VL antigen binding domains and the VH antigen binding domains together constitute a second ligand and a fourth ligand binding to a HER2 D1 epitope. The invention further relates to the tetrameric polypeptide for use in a method for the prevention or treatment of a malignant neoplastic disease, an isolated nucleic acid and a host cell for expression of the polypeptide and a method for obtaining the polypeptide. | 2021-12-23 |
20210395397 | ANTIGEN-BINDING MOLECULES COMPRISING UNPAIRED VARIABLE DOMAINS - Antibodies comprising unpaired variable domains, e.g., heavy chain variable (VH) domains, for binding antigen. Antibody comprising two immunoglobulin (Ig) chains, wherein a first Ig chain comprises a variable domain and a constant domain, and a second Ig chain comprises a constant domain, wherein the second Ig chain lacks a variable domain, leaving the variable domain of the first Ig chain unpaired. The antibody may comprise two Ig heavy chains and two Ig light chains, each heavy chain comprising a VH domain and a constant region comprising a CH1 domain, and each light chain comprising a CL domain, wherein one or both light chains lack a VL domain, thereby leaving one or both VH domains unpaired. Non-human animals (e.g., mice) engineered to produce antibodies having unpaired VH domains, involving deletion of sequence coding for light chain variable (VL) domains. Use of unpaired VH domains to generate antigen-binding molecules. | 2021-12-23 |
20210395398 | T CELL RECRUITING POLYPEPTIDES BASED ON TCR ALPHA/BETA REACTIVITY - T cell recruiting polypeptides are provided that bind the constant domain of TCR on a T cell. The polypeptides can be used in methods for treatment of cancers. | 2021-12-23 |
20210395399 | METHODS OF QUANTIFYING OLIGOSACCHARIDE PREPARATIONS - The present disclosure relates to selective analytical methods for the detection and/or quantification of an oligosaccharide preparation in a nutritional composition such as an animal feed. Also disclosed are methods of manufacturing a nutritional composition comprising an oligosaccharide preparation, the presence or concentration of which can be selectively detected or determined. | 2021-12-23 |
20210395400 | Mixed Catalyst Systems with Properties Tunable by Condensing Agent - The present disclosure provides processes for polymerizing olefin(s). Methods can include contacting a first composition and a second composition in a line to form a third composition. The first composition can include a contact product of a first catalyst, a second catalyst, a support, a first activator, a mineral oil. The second composition can include a contact product of an activator, a diluent, and the first catalyst or the second catalyst. Methods can include introducing the third composition from the line into a gas-phase fluidized bed reactor, introducing a condensing agent to the line and/or the reactor, exposing the third composition to polymerization conditions, and/or obtaining a polyolefin. | 2021-12-23 |
20210395401 | PRECURSORS AND CATALYST COMPONENTS FOR THE POLYMERIZATION OF OLEFINS - A Ziegler-Natta catalyst component precursor made from or containing a mechanical mixture of (a) distinct particles of adducts of formula MgCl | 2021-12-23 |
20210395402 | Production of Ring Polymers from Terminal Alkynes by Alkylidynes - This invention relates to a method comprising combining an alkylidyne catalyst compound and a terminal alkyne to form a ring polymer. The terminal alkyne has the formula RC | 2021-12-23 |
20210395403 | POLYMER COAGULANT AND GRAFT COPOLYMER COMPRISING SAME - The present invention relates to a polymer coagulant including methacrylamide in a preferred range and an enlarged graft copolymer prepared using same. The polymer coagulant provided in the present invention may enlarge a conjugated diene-based polymer to a suitable particle diameter range, and there are advantages of achieving excellent impact resistance and flowability of a graft copolymer prepared from the polymer. | 2021-12-23 |
20210395404 | IN-LINE TRIMMING OF DRY CATALYST FEED - A process for polymerizing polyethylene is disclosed. The process comprises contacting ethylene and at least one comonomer with a catalyst system to produce a polyolefin. The first catalyst and at least a portion of the second catalyst are co-supported to form a commonly-supported catalyst system. The catalyst system is introduced to a line as a dry-feed. The line is coupled with a polymerization reactor. A carrier fluid is added to the line to form a slurry. The slurry is introduced to the polymerization reactor. | 2021-12-23 |
20210395405 | Articles Formed From Fluorine-Containing Elastomer Compositions Using an Additive Manufacturing Method and Additive Manufacturing Methods for Thermoset Elastomer Compositions - An apparatus suitable for extruding curable polymers for forming elastomer articles using additive manufacturing, and curable fluorine-containing polymer compositions suitable for use in such an apparatus are disclosed along with an additive manufacturing method for forming a fluorine-containing elastomer article including providing a filament formed of a curable fluoropolymer composition; providing an additive manufacturing printer having a drive mechanism and a printer nozzle; feeding the filament into an additive manufacturing printer through the drive mechanism and through a longitudinal passage defined by an interior wall of a support tube, wherein the support tube extends from a first end to a second end, and wherein the second end of the support tube is positioned near an inlet to a printer nozzle; applying heat to the filament; and printing successive layers of the heated filament exiting an outlet of the nozzle onto a substrate using the additive manufacturing printer to form the fluorine-containing elastomer article. | 2021-12-23 |
20210395406 | REVERSIBLE CROSS-LINKING SYSTEM FOR POLYVINYLAMINES - A vinyl amine containing polymer comprises randomly distributed repeating monomer units having at least two of the following formulae: | 2021-12-23 |
20210395407 | POLYBUTADIENE, METHOD OF PRODUCING POLYBUTADIENE, POLYBUTADIENE COMPOSITION, TIRE, AND RESIN MEMBER - Provided is novel polybutadiene having high isotacticity. The polybutadiene has a triad isotacticity (mm) of 72% or more. | 2021-12-23 |
20210395408 | Rubber Composition and Molded Article Manufactured Therefrom - A rubber composition having excellent abrasion resistance and improved viscoelasticity properties, and a tire manufactured using the same are disclosed herein. In some embodiments, a rubber composition includes a first synthetic rubber and a second synthetic rubber, and has an interaction parameter (χ | 2021-12-23 |
20210395409 | POLYVINYL ALCOHOL-BASED RESIN, METHOD FOR PRODUCING POLYVINYL ALCOHOL-BASED RESIN, DISPERSING AGENT AND DISPERSING AGENT FOR SUSPENSION POLYMERIZATION - The present invention relates to a polyvinyl alcohol-based resin, wherein when the polyvinyl alcohol-based resin is made into a 0.1 wt % aqueous solution, an absorbance (X) at a wavelength of 320 nm in an ultraviolet absorption spectrum thereof is 0.3 or more, and a ratio (Y/X) of an absorbance (Y) at a wavelength of 380 nm to the absorbance (X) at a wavelength of 320 nm is 0.09 or more. | 2021-12-23 |
20210395410 | POLYOLEFIN TERPOLYMERS, VITRIMERS MADE THEREFROM, AND METHOD OF MAKING THE POLYOLEFIN TERPOLYMERS AND VITRIMERS - Terpolymers that include a hydrocarbon unit, an acetoacetate terminated unit and a hydroxy-terminated unit are described. Vitrimers made from these terpolymers are also described. | 2021-12-23 |
20210395411 | Polyolefin - The present invention relates to polyolefin. More specifically, the present invention relates to polyolefin having excellent dart drop impact strength, and exhibiting improved transparency, and such polyolefin has a density of 0.915 g/cm | 2021-12-23 |
20210395412 | POLYOLEFIN AND METHOD FOR PREPARING SAME - A polyolefin and a method for preparing same are provided. The polyolefin is formed by copolymerizing an olefin-based monomer and a comonomer in the presence of an olefin polymerization catalyst comprising a transition metal compound for an olefin polymerization catalyst represented by formula 1, and the weight average molecular weight (Mw) thereof may be 20,000 or less. The description of formula 1 is the same as that in the description of the invention. | 2021-12-23 |